Design and principal results



Similar documents
Malmö Preventive Project. Cardiovascular Endpoints

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Malmö Preventive Project. Cardiovascular Endpoints

Cardiovascular Endpoints

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke

Cardiovascular Endpoints

Snoring and Obstructive Sleep Apnea (updated 09/06)

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Statins and Risk for Diabetes Mellitus. Background

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Quantifying Life expectancy in people with Type 2 diabetes

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Diabetes and Heart Disease

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

definition and diagnosis of diabetes mellitus and intermediate hyperglycemia Report of a WHO/IDF Consultation

Guidelines for the management of hypertension in patients with diabetes mellitus

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

Listen to your heart: Good Cardiovascular Health for Life

Cardiovascular Effects of Drugs to Treat Diabetes

Main Effect of Screening for Coronary Artery Disease Using CT

A Population Based Risk Algorithm for the Development of Type 2 Diabetes: in the United States

Diabetes Complications

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Section 1.3 Exercises (Solutions)

Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD

Mortality Associated with Diabetes

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

Will The Coronary Calcium Score Affect the Decision To Treat With Statins?

Guide to Biostatistics

An Introduction to Medication Adherence

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Prognostic impact of uric acid in patients with stable coronary artery disease

Summary Evaluation of the Medicare Lifestyle Modification Program Demonstration and the Medicare Cardiac Rehabilitation Benefit

EUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events

Scottish Diabetes Survey Scottish Diabetes Survey Monitoring Group

Vitamin D and Cardiometabolic risk

What are the PH interventions the NHS should adopt?

HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and

Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us

Social inequalities in all cause and cause specific mortality in a country of the African region

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

HeartScore Web - based version users guide TABLE OF CONTENTS. 1. Preamble Benefits of using HeartScore Accessing HeartScore...

HYPERCHOLESTEROLAEMIA STATIN AND BEYOND

Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease

General and Abdominal Adiposity and Risk of Death in Europe

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

Pricing the Critical Illness Risk: The Continuous Challenge.

DIABETES A chronic, debilitating and often deadly disease A global epidemic Diabetes in Africa

Understanding diabetes Do the recent trials help?

Chapter 2: Health in Wales and the United Kingdom

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

Health care of non-communicable diseases and associated imprisonment factors in Mexico City's male prisons

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

Insulin Resistance and PCOS: A not uncommon reproductive disorder

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

With Big Data Comes Big Responsibility

MY TYPE 2 DIABETES NUMBERS

Carbohydrate and Lipid Disorders and Relevant Considerations in Persons with Spinal Cord Injury

Success factors in Behavioral Medicine

Plasma Testosterone Level in Male Patients with Metabolic Syndrome

Education. Panel. Triglycerides & HDL-C

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

Albumin and All-Cause Mortality Risk in Insurance Applicants

Coronary Heart Disease (CHD) Brief

Η δίαιτα στην πρόληψη του αγγειακού εγκεφαλικού επεισοδίου

The Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

The South Asian Indian Women s s Weight Loss Study. Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005

HEDIS CY2012 New Measures

Appendix: Description of the DIETRON model

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

WHAT DOES DYSMETABOLIC SYNDROME MEAN?

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Summary HTA. HTA-Report Summary. Introduction

CARDIAC REHABILITATION Winnipeg Region Annual Report

Transcription:

International Task Force for Prevention Of Coronary Heart Disease Coronary heart disease and stroke: Risk factors and global risk Slide Kit 1 (Prospective Cardiovascular Münster Heart Study) Design and principal results

TABLE OF CONTENT Slide 1: Recruitment Area Slide 2: Design Slide 3: Outcome Slide 4: Prevalence ofrisk Factors in Groups With and Without Coronary Evente Slide 5: Incidence ofcoronary Events According to HDL-Cholesterol and Cholesterol Slide 6: Prevalence ofrisk Factors in Groups With and Without Coronary Events Slide 7: The Lipid Triad and Risk ofcoronary Events Slide 8: Incidence ofcoronary Events in 8 Years in Quintiles ofthe Algorithm Slide 9: Coronary Risk Algorithm Predicts Stroke Incidence Slide 10: Risk Factors Included in Standrad Algorithm and Neural Network Analysis Slide 11: Incidence ofcoronary Events in Deciles ofrisk Predictors Slide 12: Receiver Operated Characteristics Curves for Various Risk Predictors 3 4 5 6 7 8 9 10 11 12 13 14 2

Slide 1: (Münster Heart Study): Recruitment Area The Prospective Cardiovascular Münster () Study (also known as the Münster Heart Study) was initiated in 1978 by the Institute ofarteriosclerosis Research at the University ofmünster. In several waves ofrecruitment, more than 30.000 participants aged between 16 and 65 years were recruited from among the employees of 52 large companies and the public service in Münster and the northern Ruhr a- rea, the area shaded on the slide. All participants are in continuing long term follow-up for heart disease, stroke and mortality. 3

Slide 2: (Münster Heart Study): Design This slide shows the main characteristics ofthe Study. 4

Slide 3: (Münster Heart Study): Outcome In the Study only the cohort of4849 men aged 40-65 years included a sufficient number of coronary events for valid statistical analysis on 8-year follow-up. The outcome characteristics of this cohort are shown on this slide.4381 men survived 8 years without definite nonfatal MI or stroke, 258 definite coronary events occurred. Thus, the total size of this cohort is 4639 (258 plus 4381) men. LDL-cholesterol was not determined in 138 men with triglyceride levels above 400 mg/dl, 12 of whom had coronary events. Thus for figures including data on LDLcholesterol, the total size ofthe cohort was 4501 and the number ofcoronary events was 246. 5

Slide 4: (Münster Heart Study): Prevalence of Risk Factors in Groups With and Without Coronary Events In the cohort of4639 men aged 40 to 65 years in, 258 developed a coronary event (fatal or nonfatal myocardial infarction, sudden cardiac death) within 8 years of follow-up. As shown on this slide, each ofthe classic risk factors was between 50% and three times more common in men with a coronary event than in those without such an event. 6

Slide 5: (Münster Heart Study): Incidence of Coronary Events According to HDL-Cholesterol and Cholesterol Perhaps the most important result to emerge from and other prospective epidemiological studies of coronary heart disease risk factors is the realization that risk factors do not act in isolation, but in synergistic interaction with other risk factors. That is to say, individual risk factors interact in a multiplicative rather than an additive fashion. This is illustrated in this slide which shows the interaction between total cholesterol and HDLcholesterol. Risk increases dramatically, from only 6 per 1000 in 8 years among men with a total cholesterol below 200 mg/dl and an HDL-cholesterol above 55 mg/dl at entry into the Study to a striking 382 per 1000 among men with a cholesterol above 300 mg/dl and an HDL-cholesterol below 35 mg/dl. This represents a more than 60-fold differential in risk. 7

Slide 6: (Münster Heart Study): Prevalence of Risk Factors in Groups With and Without Coronary Events In the cohort of4639 men aged 40 to 65 years in, 258 developed a coronary event (fatal or nonfatal myocardial infarction, sudden cardiac death) within 8 years of follow-up. As shown on this slide, each of the classic risk factors was between 50% and three times more common in men with a coronary event than in those without such an event. 8

Slide 7: (Münster Heart Study): The Lipid Triad and Risk of Coronary Events International Task Force for Prevention of Coronary Heart Disease In recent years, much attention has been devoted to the so-called metabolic syndrome, a complex comprising insulin resistance, obesity, hypertension, and dyslipidemia. One ofthe most commonly observed defects in this condition is the combination ofmoderately raised total cholesterol, low HDL-cholesterol, and hypertriglyceridemia (Lipid Triad). When the cohort ofmen aged 40 to 65 in was segregated using a total to HDL-cholesterol ratio of5 as a cut-off(the median in the population, see slide 5), and then further segregated according to the HDL-cholesterol and triglyceride levels, a striking gradient ofrisk was observed, ranging from 6.6% among men with an HDL-cholesterol above 35 mg/dl (0.9 mmol/l) and a triglyceride level ofbelow 150 mg/dl (1.7 mmol/l) to 15.7% among men with an HDL-cholesterol below 35 mg/dl (0.9 mmol/l) and a triglyceride level above 150 mg/dl (2.3 mmol/l). Slide 7a (on Top) shows these data in mg/dl, slide 7b (bottom) in mmol/l. 9

Slide 8: (Münster Heart Study): Incidence of Coronary Events in 8 Years in Quintiles of the Algorithm Ifthe results ofthe Study had to besummedupinone slide, this would be it. What this slide shows is the incidence ofcoronary events occurring within 8 years offollow-up in men aged 40 to 65 in, divided into fifths (quintiles) using a multiple logistic function derived from more than 50 variables measured in each man. The 8 variables listed here each make an independent contribution to risk. Taken together, they allow a more than 40- fold stratification of risk between the lowest and the highest quintile. Slide 8b shows the same results expressed on a per year basis. The mean annual risk in each quintile is as follows: 10 quintile 1: 0.05 % quintile 2: 0.13 % quintile 3: 0.31 % quintile 4: 0.86 % quintile 5: 2.26 % Allocation ofyour patients to these quintiles can be performed using the interactive program on this Website www.chd-taskforce.com/risk-english.htm

Slide 9: (Münster Heart Study): Coronary Risk Algorithm Predicts Stroke Incidence An important result of the Study was the finding that the risk algorithm for coronary events also identified those men at high risk for stroke. As shown on this slide, the rate ofincrease in risk across the quintiles ofthe algorithm was similar for coronary and cerebrovascular disease. 11

Slide 10: (Münster Heart Study): Risk Factors Included In Standard Algorithm and Neural Network Analysis The Future ofrisk Analysis: A most promising approach to risk prediction is the use ofneural networks to detect and exploit complex, non-linear interactions between risk variables. In the Study, such neural network analysis allowed utilization ofseveral variables which are shown on this slide. 12

Slide 11: (Münster Heart Study): Incidence of Coronary Events In Deciles of Risk Predictors International Task Force for Prevention of Coronary Heart Disease Improvement ofrisk Prediction using Neural Networks: As shown by the Study, a logistic regression model (standard algorithm) using 8 variables significantly improves risk prediction compared to a single risk factor such as LDL-cholesterol. Neural network improves the ability to predict risk even further. As shown in this slide, neural network analysis allocates a greater proportion of coronary events to the highest decile ofrisk. 13

Slide 12: (Münster Heart Study): Receiver Operated Characteristics Curves for Various Risk Predictors Perhaps the best measure ofthe performance ofa predictive function is the area under receiver operated characteristics (ROC)-curves. A test which perfectly discriminates between affected and non-affected individuals passes through the top left hand corner of the graph (area under curve 100%). A test with no discriminatory power follows the dashed line shown on this slide (area under curve 50%) The better a test, the more the ROCcurve deviates from this line. As can be seen on this slide the area under the ROC-curve is significantly greater with neural network analysis compared to the standard algorithm or single risk factors. 14